Lyell Immunopharma
| Type | Public |
|---|---|
| Nasdaq: LYEL | |
| Industry | Biotechnology Pharmaceuticals |
| Founded | 2018 |
| Headquarters | San Francisco, California, U.S. |
| Website | lyell |
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.